The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Sydm, just for info quote from 'unprecedented' post 14 Jan
"never understood why avacta never get a mention in any of the portion down reports - it’s because they don’t produce an avacta branded test, they are contributing to the sovereign U.K."
Markings on test may not show avacta. However, will be interesting what your wife is able to determine.
Is very likely to be a requirement within the travel industry for the foreseeable future, whether for c19 or any other virus that may be circulating. The traveller/holiday maker will pay & it will likely be included in cost of ticket. Many 1st/2nd world countries will be risk averse following this epidemic & won't relax precautions readily. Testing, one way or another, is here for my lifetime.
AP. From rns 22 July
"I am delighted that the COVID-19 BAMS assay that we are developing with Adeptrix has been accepted into the CONDOR programme. This provides us with access to patient samples and partners in UK hospitals to rapidly carry out the validation studies that are critical to progress the BAMS assay development.
There is more, but nowhere is a timeline given. And how could one be given when out of avct's hands & into Condor? Not spilt milk at all. Maybe more to do with investor anticipation & ensuing disappointment. Problem with speculation.
What we mustn't forget is that we are probably still cracking on with saliva & if successful will offer that commercially. "
In addition, the Group has made excellent recent progress with its SARS-CoV-2 lateral flow rapid antigen test programme and we anticipate data from the first clinical trial soon. Our clinical evaluation of the BAMSTM laboratory assay is ongoing at two UK clinical sites that Avacta has established and we have made significant commercial progress for all of our coronavirus testing solutions, establishing scalable routes to market for these products to meet the anticipated very high demand.
"In addition, the Group has made excellent recent progress with its SARS-CoV-2 lateral flow rapid antigen test programme and we anticipate data from the first clinical trial soon. Our clinical evaluation of the BAMSTM laboratory assay is ongoing at two UK clinical sites that Avacta has established and we have made significant commercial progress for all of our coronavirus testing solutions, establishing scalable routes to market for these products to meet the anticipated very high demand."
Lazypunter..."but I deal in facts and figures". Strange array of investments if that's so.
Why did you invest in Avacta? Did you think it was something that would offer a tasty short term return? If so, demonstrates lack of understanding in the opportunity.
I also think Avacta's main focus is cancer therapeutics, however, Covid19 has provided the opportunity to develop, exponentially, their diagnostic solution(s). Get the lfd(s) right, & quite possibly the same tech will be a valuable asset in future battles against known, & as yet unknown, viruses.